In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Insulet announces private placement of $700mm in notes

Executive Summary

Insulet Corp. (developer of the Omnipod insulin management system) announced an upsized private placement of $700mm (net $684.3mm) aggregate principal amount of convertible senior notes due 2026. The notes bear interest at a rate of 0.375% and can be converted in cash, stock, or a combination. The conversion rate will initially be 4.4105 shares of common stock per $1k principal amount of notes, or $226.73 per Insulin share (its shares are currently averaging $154.65). The company is also granting the initial purchasers an option to purchase another $100mm notes. Insult announced it is entering into capped call transactions and will use some of the proceeds to fund those transactions. Additional funds will be used to repurchase $225mm aggregate principal amount of the outstanding 1.25% convertible senior notes due 2021.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
    • Monitoring Equipment & Devices
  • In Vitro Diagnostics
    • Glucose Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • Private Placement

Related Companies